Journal of Clinical Pathology. Published Online First: 28 March 2006. doi:10.1136/jcp.2005.026435. [Link]
Anna Scattone 1, Antonio Pennella 2, Mattia Gentile 3, Marina Musti 4, Pietro Nazzaro 5, Antonia Lucia Buonadonna 3, Andrea Marzullo 1, Donenica Cavone 4, Lucio Pollice 1 and Gabriella Serio 1*
1 Dpt. of Pathology, Medical School, University of Bari, Italy
2 Dpt. of Surgery and Pathology, Medical School, University of Fo, Italy
3 Medical Genetics, "De Bellis" IRCCS Hospital, Castellana Gro, Italy
4 Dpt. of Internal and Public Medicine, Medical School, University, Italy
5 Dpt. of Clinical Methodology, Medical School, University of Bari., Italy
* To whom correspondence should be addressed. E-mail: email@example.com.
Accepted 23 November 2005
Background: Malignant deciduoid mesothelioma (MMD) is a rare variant of epithelioid mesothelioma. Generally, this tumour generally has poor prognosis, and it can be asbestos-related. Aim of the study was to identify peculiar genetic alterations responsible for critical phases in MMD pathogenesis and their with prognostic significance.
Methods: Comparative Genomic Hybridization (CGH) was performed oin six cases of malignant pleural deciduoid mesothelioma, four sporadic and two familial. All cases were asbestos-related. Four patients died within during follow-up. Mean survival was 29.5 +/- 14.2 months (range 12-43).
Results: In all tumours genetic abnormalities were found in all the tumour tissues being most frequently chromosomal gains of 1p, 12q, 17, 8q, 19, and 20. Losses occurred at 13q, 6q, and 9p. Survival was longer in those patients who presented a smaller number of losses in the tumoral chromosomes (</= 2).
Conclusions: Although deciduoid mesotheliomas present numerous genetic changes, we highlighted demonstrated that certain chromosomal regions are preferentially affected. Our findings show that the number of losses is predictive of the clinical outcome for this subtype of mesothelioma subtype.
Keywords: CGH, Genetic, Mesothelioma, Pleural